Eli Lilly’s TOGETHER-PsO trial links obesity treatment with psoriasis improvement
Eli Lilly's Taltz and Zepbound show broader immune and metabolic biomarker changes in psoriasis, building on Phase 3b skin clearance results.
Pharma & Biotech
Medical Devices & Diagnostics
Ginkgo Bioworks joins $1.5bn NSF X-Labs push with autonomous laboratory access
Ginkgo Bioworks will provide in-kind robotic laboratory access and protein testing services to researchers involved in the National Science Foundation's $1.5 billion X-Labs initiative. The announcement strengthens its position in publicly supported autonomous research infrastructure, but the programme's headline funding is not a contract award to Ginkgo.
Pharma & Biotech
Why GSK’s wet-lab validation gives Chai Discovery a stronger pharmaceutical industry foothold
GSK expands Chai Discovery AI collaboration after wet-lab success. See what the binding results establish and what remains unproven.
Pharma & Biotech
Eli Lilly just cut basal insulin dosing from 365 injections to 52. Can Onswik catch Novo Nordisk’s Awiqli?
Eli Lilly and Company has secured U.S. Food and Drug Administration approval for Onswik, its once-weekly basal insulin for adults with type 2 diabetes, bringing a second weekly insulin into the U.S. market and shifting the competitive question from regulatory feasibility to prescribing, access and real-world adoption.
Pharma & Biotech
Viking Therapeutics stock drops after hours as $400m raise follows 36% VK2735 surge
Viking Therapeutics is seeking $400 million through stock and convertible-note offerings immediately after VK2735 obesity data sent its shares sharply higher, as the company accelerates Phase 3 development and explores monthly and every-other-week maintenance dosing.
Pharma & Biotech
Eli Lilly puts retatrutide, Foundayo and eloraTZP on one stage as obesity pipeline widens
Eli Lilly will use the European Association for the Study of Diabetes 2026 meeting to detail Phase 3 retatrutide results, new Foundayo data and the first Phase 2 readout for eloraTZP, revealing how the company intends to segment an increasingly competitive obesity and diabetes market.
Pharma & Biotech
Lilly’s Zepbound plus Taltz sustains stronger psoriasis and psoriatic arthritis outcomes at one year
Eli Lilly and Company says one-year Phase 3b data from TOGETHER-PsO and TOGETHER-PsA show sustained or deeper improvements when Zepbound and Taltz are used together in patients living with psoriatic disease and obesity.
Pharma & Biotech
Ascletis starts 4,600-patient Phase 3 trial of oral GLP-1 weight-loss drug ASC30
Ascletis Pharma has dosed the first participant in a 4,600-person global Phase 3 program for ASC30, a once-daily oral small-molecule GLP-1 receptor agonist that produced up to 7.7% placebo-adjusted weight loss after 13 weeks in Phase 2.
Pharma & Biotech
Can low doses of Ozempic, Wegovy, Mounjaro and Zepbound still cause weight loss?
A new real-world study of sustained low-dose semaglutide and tirzepatide found measurable weight loss without escalation to standard maintenance doses, but researchers stress that prescription records do not prove intentional GLP-1 microdosing and the observational findings cannot establish cause and effect.
Pharma & Biotech
Mounjaro is no longer just about blood sugar and weight. FDA approval pushes Lilly into a bigger cardiovascular fight
The FDA has approved Eli Lilly and Company’s Mounjaro to reduce cardiovascular death, heart attack and stroke risk in high-risk adults with type 2 diabetes, significantly broadening the clinical case for tirzepatide beyond glucose control and weight reduction.